Praeventix Overview
- Year Founded
-
2015
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$12.4M
- Investors
-
1
Praeventix General Information
Description
Developer of serotonergic therapeutics designed to treat dermatologic, autoimmune, and neurodegenerative diseases. The company utilizes selective receptor antagonists to target itch pathways in the skin and inflammatory pathways in the gastrointestinal tract, enabling healthcare providers to offer first-in-class treatments for chronic pruritus, inflammatory bowel disease, and cocaine use disorder.
Contact Information
Website
www.praeventix.comCorporate Office
- 665 Stockton Drive
- Suite 200H
- Exton, PA 19341
- United States
Corporate Office
- 665 Stockton Drive
- Suite 200H
- Exton, PA 19341
- United States
Praeventix Timeline
Praeventix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 04-Sep-2026 | $12.4M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | 19-Apr-2023 | Completed | Pre-Clinical Trials |
Praeventix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Praeventix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Praeventix Patents
Praeventix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025161894-A | Novel functionalized lactams as modulators of 5-hydroxytryptamine receptor 7 and their method of use | Pending | 13-Nov-2019 | ||
| AU-2020381460-A1 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Active | 13-Nov-2019 | ||
| AU-2020381460-B2 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Active | 13-Nov-2019 | ||
| CA-3160801-A1 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Pending | 13-Nov-2019 | ||
| EP-4058455-A1 | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | Pending | 13-Nov-2019 | C07D471/10 |
Praeventix Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tellus BioVentures | Venture Capital | Minority |
Praeventix FAQs
-
When was Praeventix founded?
Praeventix was founded in 2015.
-
Where is Praeventix headquartered?
Praeventix is headquartered in Exton, PA.
-
What industry is Praeventix in?
Praeventix’s primary industry is Drug Discovery.
-
Is Praeventix a private or public company?
Praeventix is a Private company.
-
What is Praeventix’s current revenue?
The current revenue for Praeventix is .
-
How much funding has Praeventix raised over time?
Praeventix has raised $16.7M.
-
Who are Praeventix’s investors?
Tellus BioVentures has invested in Praeventix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
